Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:public_company
|
| gptkbp:acquiredBy |
gptkb:Allergan
|
| gptkbp:acquisitionYear |
2020
|
| gptkbp:CEO |
gptkb:Richard_A._Gonzalez
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:dividendPaying |
true
|
| gptkbp:foundedYear |
2013
|
| gptkbp:hasCompany |
gptkb:AbbVie_Inc.
|
| gptkbp:headquartersLocation |
gptkb:North_Chicago,_Illinois,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
NYSE: ABBV
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:ISIN |
US00287Y1091
|
| gptkbp:listedOn |
gptkb:New_York_Stock_Exchange
|
| gptkbp:marketCap |
over $250 billion (2024)
|
| gptkbp:numberOfEmployees |
~50,000
|
| gptkbp:products |
gptkb:Humira
gptkb:Imbruvica gptkb:Rinvoq gptkb:Skyrizi gptkb:Venclexta |
| gptkbp:researchInterest |
immunology
neuroscience oncology virology eye care |
| gptkbp:S&P500Component |
true
|
| gptkbp:sector |
gptkb:insurance
|
| gptkbp:spinOff |
gptkb:Abbott_Laboratories
|
| gptkbp:stockSymbol |
gptkb:NYSE
gptkb:ABBV |
| gptkbp:website |
https://www.abbvie.com/
|
| gptkbp:bfsParent |
gptkb:Abbott_Laboratories_(spinoff)
|
| gptkbp:bfsLayer |
8
|